Regeneron
Regeneron injects $100 million and 300 new roles into Irish production facility
October 26, 2017Manufacturing and Production Regeneron, Sanofi, manufacturing, pharma
Sanofi subsidiary Regeneron has announced its intention to expand its production plant in Limerick, Ireland – the largest scale bulk …
Peanut allergies? There’s a clinical trial looking to fix that
October 17, 2017Manufacturing and Production, Research and Development Aimmune, Regeneron, Sanofi, biotech, drugs, peanuts, pharma, pharmaceutical
Aimmune Therapeutics, a biotech company developing treatments for food allergies, announced that it has entered into a clinical trial collaboration …
Sanofi and Regeneron’s projected blockbuster gains EU approval
September 28, 2017Sales and Marketing Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi and Regeneron have big hopes for their treatment Dupixent, and it has taken an important step towards reaching the …
Sanofi/Regeneron new asthma data bolstered by potential indications
September 13, 2017Research and Development Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi and Regeneron’s Dupixent is predicted to grow to be one of the largest selling drugs in the industry but …
Regeneron abandons respiratory syncytial virus therapy after late-stage failure
August 15, 2017Manufacturing and Production, Research and Development RSV, Regeneron, pharma, pharmaceuticals, respiratory syncytial virus
Regeneron has announced that the failure of suptavumab, its experimental treatment for respiratory syncytial virus (RSV), in late-stage trials, the …
New potential blockbuster RA treatment enters European market
June 27, 2017Sales and Marketing AbbVie, Humria, Kevzara, Regeneron, Sanofi
The world’s biggest selling drug, AbbVie’s Humira with $16 billion in sales last year, has a new rival in the …
Novartis receives positive news in eye drug P3 studies
June 20, 2017Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron
Novartis has achieved positive feedback from its two Phase 3 studies into its eye drug RTH258 (brolucizumab), which found it …
Sanofi and Regeneron posts positive Praluent cholesterol data
June 12, 2017Research and Development, Sales and Marketing Regeneron, Sanofi, praluent
Sanofi and Regeneron were able to update its PCSK9 therapy Praluent with the positive data showing it could reduce levels …
FDA approves first-ever atopic dermatitis biologic treatment
March 31, 2017Medical Communications, Sales and Marketing Dupixent, Regeneron, Sanofi, atopic dermatitis, biologic
Sanofi and Regeneron’s Dupixent (dupilumab) has become the first biologic medicine to be approved by the FDA for the treatment …
Breakthrough eczema drug given FDA approval
March 29, 2017Research and Development, Sales and Marketing Dupixent, Regeneron, Sanofi
Regeneron and Sanofi have received approval for its eczema treatment, Dupixent, by the FDA. The treatment will be the first …
GSK and Regeneron partner with Biobank to analyse 500,000 genetic profiles
March 23, 2017Research and Development Biobank, GSK, Regeneron
GlaxoSmithKline and Regeneron Pharmaceuticals are to band together in a joint effort with UK Biobank – “the world’s most detailed …
Sanofi & Regeneron deflect Amgen’s legal marketing block on Praluent
February 9, 2017Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, praluent
Sanofi and Regeneron have successfully won in a US Court ruling calling for the suspension of the permanent injunction of …
Sanofi & Regeneron’s arthritis drug scores first approval following FDA rejection
February 1, 2017Research and Development, Sales and Marketing Actemra, Humira, Kevzara, Regeneron, Roche, Sanofi, sarilumab
Kevzara (sarilumab), a interleukin-6 (IL06) receptor antibody developed by Sanofi and Regeneron and the first real competitor to Roche’s Actemra …
Regeneron agrees ownership of HQ for $720m after 25 years
January 25, 2017Manufacturing and Production, Medical Communications Regeneron
After leasing the property for 25 years, Regeneron has agreed to take ownership of its headquarters and buy the Landmark …
Amgen’s patent win upheld against Sanofi-Regeneron
January 4, 2017Medical Communications, Research and Development Amgen, Regeneron, Sanofi, patent
In March 2016, Amgen won two major patent cases against Sanofi and Regeneron over their drug, Praleunt, after it was …
Latest content
